Nintedanib, one of the two drugs specifically approved for IPF, is an intracellular inhibitor of tyrosine kinase receptors, targeting platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) receptor and other non-receptor tyrosine kinases (RTKs) of the SRC family that elicits antifibrotic responses on cardiac muscle in animal model of pulmonary disease (Rol et al., 2019). Here, VEGFA is linked to idiopathic pulmonary fibrosis.